Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with variousp53 mutants: Involvement of AP-1
- 12 April 1999
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 81 (2) , 236-242
- https://doi.org/10.1002/(sici)1097-0215(19990412)81:2<236::aid-ijc12>3.0.co;2-r
Abstract
In human ovarian carcinomas, the p53 tumor-suppressor gene is frequently mutated. Interleukin-6 (IL-6) in these tumors is known to stimulate tumor-cell proliferation. In order to evaluate the effect of several p53 phenotypes on the IL-6 promoter activity, the human ovarian wild-type (wt)-p53 cell line A2780 was stably transfected with an empty plasmid (CMV) or (m)-175-, m-248- or m-273-p53. Electrophoretic mobility-shift assays revealed differences in activator protein-1 (AP-1) DNA-binding activity in the various clones. The CMV and m-273 clone had comparable amounts of AP-1. The m-175 clone displayed the least and m-248 the most pronounced AP-1 binding. Supershift analysis of AP-1/DNA complexes with antibodies against the AP-1 sub-units, c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB, and JunD, revealed that the AP-1/DNA complexes in the various clones had different compositions. Fra proteins were basically present only in m-175 and m-248 AP-1. IL-6-promoter activity was evaluated in the presence and absence of the AP-1 binding site which showed that the m-175-transfected clone has a transcriptional suppressing AP-1, whereas the CMV and the m-273 clones have an activating AP-1. Exposure of the p53 clones to tumor-necrosis factor-α (TNF-α) clearly altered the AP-1/DNA complex composition. IL-6-promoter activity was enhanced by TNF-α irrespective of the presence of an AP-1 binding site, while the degree of activation differed in the various clones, being most pronounced in the m-175 and m-248 clones. The results demonstrate that the basic and activated IL-6-promoter activity is differently regulated in the various p53 clones, possibly due to alterations in the AP-1 composition. Int. J. Cancer 81:236–242, 1999.Keywords
This publication has 33 references indexed in Scilit:
- p38 and Extracellular Signal-regulated Kinase Mitogen-activated Protein Kinase Pathways Are Required for Nuclear Factor-κB p65 Transactivation Mediated by Tumor Necrosis FactorJournal of Biological Chemistry, 1998
- Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (il-6), interleukin-lβ (IL-Iβ), interleukin-11 (IL-11) and tumour necrosis factor-α (TNF-α) in p53-characterised human ovarian carcinomasEuropean Journal Of Cancer, 1997
- Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2Journal of Biological Chemistry, 1997
- Mechanism of the Tumor Necrosis Factor α-mediated Induction of Endothelial Tissue FactorPublished by Elsevier ,1995
- Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-JunNature, 1994
- p53 mutant His175identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6FEBS Letters, 1994
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- The biology of ovarian cancerCurrent Opinion in Oncology, 1993
- Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells.Proceedings of the National Academy of Sciences, 1988
- Reversal of Adriamycin Resistance by Verapamil in Human Ovarian CancerScience, 1984